CURRICULUM VITAE OF

. GREGORY E. CAPLINGER, M.D., D.Sc .

. ..

"l: ·. I .,' ' •

BRITISH WEST INDIES MEDICAL EDUCATION FOUNDATION

This is to state GRm>RY FARL CAPLINGER, M.D., o.sc. has

registered his/her Curriculum Vitae (cv.) with our organization. All credentials

have been verified and found to be correct.

TOTAL PAGES

REGISTRATION NUMBER

DATE OF REGISTRATION

68 .

004808

August 17, 1992

Date I

BRITISH WEST INDIES MEDICAL EDUCATION FOUNDATION C/O Town Centre Mall · Misick & Stanbrook Turks & Caicos Islands, British West Indies Attn: Dr. Christopher Beauvoisin

-------. ---- ·. --------

1g94 --

-

... , ,

OFFICIAJ, REGISTRATION

This is to state that Gregory E. Caplinger

registered credentials with this Foundation. following have been completed:

credentials Verified

has The

Credentials Verified and investigated at each institution and facility and found to be correct as contained herein

Registered and Certified

SEAL

TO BE VALID THIS MUST BE SEALED AND EACH PAGE MUST BE STAMPED WITH THE REGISTRATION NUMBER.

Pages 68

004808

CURRICULUM VITAE OF

GREGORY E. CAPLINGER, M.D., D.Sc.

NO PART OF THIS CURRICULUM VITAE MAY BE

COPIED OR RELEASED TO A THIRD PAR1Y WITHOUT

THE CONSENT OF THE AUTHOR. RELEASE OR

TRANSldII.IAL OF SUCH IS A VIOlATION OF PRIVACY

AND MAY RESULT IN VIOLATION OF CRildINAL LAW(S)

AND THUS BE PROSECUTABLE •

..

CURRICULUM VITAE OF

GREGORY E. CAPLINGER, M.D., D.Sc.

EDUCATION

Elementary and High School

B.A. in Biology/ Chemistry

Special Studies

M.S. Studies

M.O.

M.O.

•

M.D.

D.Sc.

Anderson High School

Indiana University, Bloomington, Indiana USA

Anderson University, Indiana USA Special Studies in Endocrinology (G .P.A. - 4.0)

Ball State University / Muncie, Indiana USA All coursework and research was completed ( only needed to write a Thesis to receive the M.S.) studies were In Physiology and Biochemistry (Dr. Larry Gamion - Advisor)

M.C.S.C. Institute Great Britain, U.K. Graduated: Magna Cum Laude

British West Indies Medical College British West Indies This was a special program in Complementary Medicine with validation of previous coursework. Graduated: Magna Cum Laude

Universidad Aut6noma de Santo Domingo Revalidation of Doctor of Medicine (M.D.)

Sussex College of Technology Sussex, England, U.K. (Biochemistrynmmunology - Thomas J. Winters, M.D., Ph.D. and Bruce Copen, Ph.D. - Research and Dissertation Advisors) This program was In conjunction with my medical education. All coursework was completed In 1982. Thereafter, I continued my research and wrote my dissertation. I took my oral examinations In April, 1987. Graduated with Special Honors: Magna Cum Laude

1971 -1975

1971 -1975

1975-1977

1979-1982

1982-1984

1981 -1987

r· oo4sos,

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc.

Doctor of Jurisprudence (J.D.)

SPECIAL EDUCATION

Doctor of Naturopathic Medicine

N.M.D.* Doctor of Nutritional Medicine

* Ad Eundem - Based on prior education

TRAINING

Internship

Resident

Northwestern California University, School of Law This is an external program in law for the professional Anticipated graduation: Summer 1994

Anglo American Institute of Drugless Therapy, ScoUand U.K. Program in Naturopathic Medicine for primary care practitioners Graduated: 96% score out of 100%

John F. Kennedy College Colorado Springs, Colorado USA

M.C.B.C. Institute Great Britain, U.K.

M.C.B.C. Institute / Sussex CoUege of Technology This was a rotating residency and fellowship In Internal Medicine, Clinical Oncology and Immunology. The program involved rotations at various clinics, hospitals and academic facilities

Sussex General Hospital Chief resident - Internal Medicine Rotating residency fulfilling all Internal medicine requirements

PAGE 2 OR23

1982-1984

1987

1982

1982-1987

r 004aoa

CURRICULUM VITAE GREGORY EARL CAPLINGER, M.D., D.Sc.

"FELLOWSHIP{S) / SPECIAL ROTATION RESIDENCY

-

Florida Degeneraflve Disease Center Internal Medicine - Clinical Oncology Fellow

Caribbean Oncology Center Intensive 2-3 week clinical rotations every 3-4 months

Sussex General Hospital Special Fellow - Immunology The Reside11cy, Fellowship and most clinical training involved rotating from one facility to another during the years 1982-1988 The program allowed the advanced standing student to have varied experiences while supervised

Training included: I. Clinical Medicine - Internal Medicine

(Two Years) Rotations in: o Harvard Medical School, Dept of Continuing

Education (classes, conferences) (Grades/Certificate attached) Cardiology Dermatology Hematology Nephrology Gas1roenterology Immunology Rheumatology Endocrinology Oncology Neurology Infectious Diseases Pulmonary

o Sussex Co0ege of Technology

PAGE 30F23

1982-1984

1983-1987

1982-1988 (Total Years)

ll 1, l .

CURRICULUM VITAE GREGORY EARL CAPLINGER, M.D., D.Sc.

II. conical Oncology (Three Years) o Florida Degenerative Disease Center o Sussex College of Technology Topics:

PAGE 40F23

Oncologic Emergencies: Tracheal Obstruction, Superior Vena Cava Syndrome, Ureteral Obstruction, Mass Lesion in the Brain, Spinal Cord & Nerve Root Compression, Meningeal Tumor Infiltration, Fever & Neutropenla, Disseminated ln1ravascular Coagulation, Hypervlscosity, Hypercalcemla, Adrenal Insufficiency & Pituitary Insufficiency, Syndrome of Inappropriate Antidluretic Hormone Secretion, Hypoglycemia

Diagnostic Probl~ms: Fever of Unknown Origin, Lymphadenopathy, Skin Disorders, Thyroid Nodule, Hoarseness, Pulmonary Nodules, Pleural Effusion, Breast Lump, Jaundice, Hepatomegaly, Splenomegaly, Gastric Ulcer, Colon Polyp, Hematurla, Abnormal Vaginal Bleeding, The ovarian Mass, Testicular Mass, Prostate Nodule, Paraneoplastic Syndromes: Ectopic Hormone Production, Paraneoplastic Syndromes: Cutaneous, Connective Tissue, Osseous and Neuromuscular Disorders

The Primary or Regional Malignancy: General Principles of Management, Skin Cancer, Melanoma, Central Nervous System, Head & Neck Cancers, Thyroid Cancer, Breast Cancer, Breast Cancer-Adjuvant Therapy, Small-Cell Carcinoma of the Lung, Non­Small-Cell Carcinomas of the Lung, Esophageal Cancer, Stomach Cancer, Colorectal Cancer, Pancreatic Cancer, Carcinoid, Renal Carcinoma, Bladder Cancer, Prostate Carcinoma, Testis Cancer, 0varian Carcinoma, Carcinoma of the Cervix, Endometrial Carcinoma, Bone Tumors, Soft-Tissue Sarcomas

Relapsing or Metastatic Malignancy: General Principles of Management, Metastases from Unknown Primary Sites, Melanoma, Brain Tumors, Head & Neck Cancer, Thyroid Cancer, Breast Cancer, SmaD-Cel Carcinoma of the Lung, Non-Small-Cell Carcinomas of the Lung, Esophageal Cancer, stomach Cancer, Colorectal Cancer, Pancreatic Cancer, Carcinoid, Renal Carcinoma, Bladder Cancer, Prostate Carcinoma, Testis Cancer, 0vartan Carcinoma, Carcinoma of the Cervix, Endometrlal Carcinoma, Osteogenic Sarcoma, Soft­Tissue Sarcomas

,•, . ' .· ,>'..-.J

r 00480~

,,

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 50F23

Lymphomas & Hematologic Malignancies: Hodgkin's Disease -Diagnosis & Staging, Hodgkin's Disease - Treatment, Non-Hodgkin's Lymphomas-"lndolenf' Histologies, Non-Hodgkin's Lymphomas­"AggressiVe" Histologies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Non-Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma

Treatment: Problems of Surgery, Problems and Toxicities of Radiation Therapy, Chemotherapy-Principles, Alkylating Agents­Cyclophosphamlde, 5-Fluorouracil, Methotrexate, Cytosine Arablnoside, The Anthracy"'~ne Antibiotics - Oaunomycin & Adrtamycin, Bleomycln, The Plant Alkaloids - Vincrtstine & Vlnblastine, Nltrosoures, other Antineoplastic Agents & Treatments, Cis­Dlamminedichloroplatinum (COOP) (Clsplatln), Organ-Specific Chemotherapy Toxicities, Combined Modality Problems - Radiation Therapy & Surgery, Combined Modality Problems - Radiation Therapy & Chemotherapy

Management Problems: Psychosocial Aspects of Patient Care, Pain, Hemoptysis, Pleural Effusion, Pericardia! Effusion, Hepatic Metastases & Hepatocellular Carcinoma, Bowel Obstruction, Renal Failure, Bone Metastases, Viral Infections Fungal & Protozoa! Infections

Staging: Head & Neck Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Renal Carcinoma, Bladder Cancer, Prostate Cancer, Testicular Carcinoma, ovarian Cancer, Cervical Cancer, Endometr1al Cancer

,

I .~ ·l ' 1

., '

004808 :, ;~.

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. I

PAGE 60F23 I

•

Ill. Clinical Immunology (Two Years) o Florida Degenerative Disease Center o Sussex College of Technology Topics: Basic Immunology: Historical Background of Immunology Immune System: An Overview, lmmunogeniclty & Antigenic Specificity, lmmunoglobullns I: Structure & Function, lmmunoglobullns II: Gene Organization & Assembly, Human Major Hlstocompatlbility HLA

· Complex, Development & Structure of Cells In the Immune System, Cellular Interactions In the Expression & Regulation of Immunity, Mediators of Cellular Immunity, Phagocvtic Cells: Chemotaxis & Effector Functions of Macrophages & Grar ,ulocytes {Macrophages, Granulocytes), Complement System, Immune Mechanisms In Tissue Damage Autoimmunity, Clinical Transplantation, Secretory Immune System, Immunity & Infection, Tumor Immunology, Immediate Hypersensitivity, lmmunosuppression, lmmunopotentiation & Anti­Inflammatory Drugs, Effects of Sex Hormones, Nub'ition & Aging on the Immune Response, Reproductive Immunology

Immunologic Laboratory Tests: Clinical Laboratory Methods for Detection of Antigens & Antibodies, Clinical Laboratory Methods for Detection of Cellular Immune Function, Blood Banking & lmmunohematology

Clinical Immunology: Immunodeficiency Diseases, Rheumatic Diseases, Hematologic Diseases, Allergic Diseases, Gastrointestinal & Liver Diseases, Pulmonary & Cardiac Diseases, Renal Diseases, Dermatologlc Diseases, Infectious Diseases, Endocrine Diseases, Neurologic Diseases, Eye Diseases, Parasitic Diseases, Oral & Dental Diseases, Immunization, Experimental lmmunotherapy

:-.-, ....

004808

CURRICULUM VITAE :·',. ',_ .

GREGORY EARL CAPLINGER, M.D., D.Sc.

CONTINUING EDUCATION - MEDICINE *

June 1991 Medical School Review of Internal Medicine

October 1991 Harvard Medical School Review of Cardiology

December 1991 British West Indies Medical College Clinical Oncology for the Oncologist

PAGE 70F23

January 1992 - December 1993 Stanford University School of Medicine - Scientific American Medicine Review Intensive review of internal medicine with regular monthly reviews and examinations

January 1992 - December 1993 American College of Surgeons Care of 1he Surgical Patient- Scientific American Medicine Review Intensive review of surgery and surgical techniques with regular monthly reviews and examinations

March 1992 Centro de lnvesligaciones M6dico y Quinlrgica {CIMEQ) - Havana, Cuba This Involved seminars and training in the area of Internal Medicine {General), Oncology and Immunology

June 1992 Centro de lnvestigaciones M6dico y Quinlrglca {CIMEQ)- Havana, Cuba This i'lvolved seminars and training in the area of Internal Medicine (General), Oncology and Immunology

September 1992 Centro de lnvestigaciones Medico y Quinlrgica {CIMEQ)- Havana, Cuba · This ilvolved seminars and training In the area of Internal Medicine (General), Oncology and Immunology

January 1993 Centro de lnvestigaclones M6dico y Qulnlrglca (CIMEQ) - Havana, Cuba This Involved seminars and training In the area of Internal Medicine (General), Oncology and Immunology

..... ::;::,

• Continuing Education Certificates are attached In the "Addltional Section."

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 80F23

March 1993

February 1991

Centro de lnvestigaciones Medico y Quinlrgica {CIMEQ) - Havana, Cuba Ttis involved seminars and training in the area of Internal Medicine (General), Oncology and Immunology

International Internal Medicine Conference

January 1987 - December 1990 Internal Medicine Rotations wilh clinical oncology emphasis. Special program for certification in various aspects of oncology and internal medicine - Involved multiple visits to facility

1984-1986

1985

1984

1983 & 198-t

November 1987

October 1987

September 1987

July 1987

May 1987

California, USA

Harvard Medical School Department of Continuing Education Intensive Review of Internal Medicine

American Medical Association The Neurological Examination

University of Atlanta Homeopathy Review

American Academy of Medical Preventics

Harvard Medical School / Brigham and Willlams Hospital / Beth Israel Hospital - Boston, Massachusetts USA Cardiology Update for the Practicing Physician

Most of current on-going education Is at Harvard Medical School, Department of Continuing Education With course emphasis In Internal Medicine (Immunology and Oncology)

Georgetown University, School of Medicine Washington, D.C. USA Applied Thermology

Harvard School of Medicine Boston, Massachusetts USA Cancer Medicine

First International Congress on Altematlve Medicine Atlanta, Georgia USA

American Society of Clinical Oncology Atlanta, Georgia USA

004808

I

' '.l

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 90F23

CURRENT RESEARCH AND PROFESSIONAL ACTIVITIES

0Jren1IY pllSUing research ii immunology wilh emphasis on developing protocols, treatment regimens and possible new drugs in immunologically related diseases - thus, primary interest is research with cliniealapplications

POSITIONS

1993 - Current

1993 - Current

1993 - Current

1992-Current

1992 - Current

1991 - Current

1991 - Current

1991 -1992

lmmuno Pharmaceuticals Director of Clinical Research - lmmuno Oncology DMsion Dominican Republic

Notre Dame de Lafayette University Adjunct Professor of Physiology and Health Science Colorado, USA Campus

American Nutrimedical Association Senior Vice President in charge of: - Legal Affairs - Credential Services

M"anister of Health British West Indies Health Confederation British West Indies

UFHEC - School of Medicine Dominican Republic Consultant Curriculum Development

Florida Degenerative Disease Center Miami, Florida USA

Sussex General Hospital England, U.K. Chairman Department of Cllnlcal Oncology and Immunology

UTESA Dominican Republic Professor of Medicine

004808 =•, .

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 10 OF 23

1990 - Current

1989 - Current

1988-1993

1986-1988

1987

1986

1986

1984-1987

1984

1974-1977

International Center of Oncology Research England, U.K. Director of Clinical Research

British West Indies Medical College Turks and Caicos, British West Indies Dean of Medical College / Professor of Medicine

Director of Research, California International Oncology Research Center Callfomia, USA

American College of Naturopathlc Medicine Colorado Springs, Colorado USA Vice - Chairman

Guest Lecturer - Mundial School of Medicine in Immunology and Oncology Dominican Republic

Caribbean Oncology Center Director of Clinical Oncology Research

John F. Kemedy College of Nutrlmedlcal Arts and Sciences Colorado Springs, Colorado USA Professor of Nutrltlonal Medicine (VISiting)

British West Indies Medical College British West Indies Chairman - Department of Medical Sciences (VISlllng position with teaching responsibilities every three months)

Board of Directors of the International Institute for Research on Metabolic Diseases and Cancer Lisbon, Portugal .

Ball State University Muncie, Indiana · Director of Research in 0varian Metabolism

'it ..

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 11 OF 23

1976

1975-1977

1975

1974

Indiana University - School of Medicine Ball State University, Muncie, Indiana USA Teaching Assistant in Medical Physiology at the B.S.U. Campus

Ball state University - School of Nursing Muncie, Indiana Lecturer In anatomy, physiology and medical embryology

Indiana University Bloomington, Indiana Teaching Assistant In biology

Anderson University Anderson, Indiana Assistant Professor/ Lecturer in blolcgy and endocrinology

I

-~t 0048 08

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 12 OF 23

HONORS AND AWARDS

eutstandlng Research Scientist Award for Clinical Applications in Immunological Diseases (1993).

Reseaf"Ch Award / Grant for Studies In Oncology - British West Indies Medical Education Foundation (1993)

Five Hundred Leaders of Influence, The American Biographical Institute, USA - A biographical publieation of 1he most influential persons in the world. (1993 - nominated)

Jotm F. Kennedy Memorial Institute of Health Sciences, Homeopathic Therapeutics - Botanical and Nutritional Biomedicine (1985 - present)

Alpha Zi Omega, Nutritional Medical Honor Society (1985- present)

Recipient of Caribbean International Prize in Medicine (February 1987) Also given Research Grant for continued studies in lmmuno-Therapy

Doctor of the Year (1986) - American Nutritional Medical Association

Nominated for biographical listing In the International Directory of Distinguished Leadership - American Biographical Institute (1986)

Research Award in Clinical Nutrition - American Holistic Health Sciences Association (1986)

Nomilated for1he King Faisal International Prize in Science - Kingdom of Saudi Arabia (Summer 1985)

Special Award in Clinical Nutrition - British West Indies Medical College (January 1, 1985)

Cold Laser Therapy in Cancer - Research Project for Oynatronics and F .O.A. (1982-1984)

Psysianlhropist Award in Clinical Research -American Holistic Health Sciences Association (January 2, 1984)

Special Award in Clinical Research - M.C.B.C. Institute, Great Britain U.K. (July 1, 1982)

Distinguished Achievement In Nutrition, Muncie, Indiana (September 5, 1981)

Phi Eta Sigma (National CoDeglate Honor Society for Academic (Excellence)

Sigma Zeta Honorary Science Society

004808

.):;

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc.

BOARD CERTIFICATIONS

8rfllsh College of Physicians and Surgeons Loncton, England U.K. Board certified - Internal Medicine / Clinical Oncology (#321 O) May 12, 1988

Br1tiSh College of Physicians and Surgeons LondOn,England U.K. Board Certified - Clinical Immunology (#572) May 12, 1988

Fe0ow - Sussex College of Technology 1991 SUSsex, CJ<. Special acknowledgement of past graduates for continued excellence in Science

American College of International Physicians FeOow (#4026) 1992

International Alliance of Nutrimedical Associations Board of Examiners

PAGE 130F23

Board Certifications (1992): Nutrimedical Care #7546, Oncological Care #7546, Immunological 17546

International College of Clinical Oncology (#1121) Fellow (1992)

caribbean College of Oncology Olplomate (1987)

;~

004808 t f

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc.

UCENSE(S} / REGISTRATION(S}

British West Indies Medical Education Foundation lntemational Board Examination Registration #0219 / Physician British West Indies

British West Indies Medical Education Foundation Physician Registration/ #0121 Specialty Registration (Internal Medicine/Oncology) British West Indies

United Kingdom - England U.K. Homeopathic Medical Association Physician Registration United Kingdom

United states of America Medical Consultant (Restricted to consulting) License / Registration #321

International Alliance of Nutrimedical Associations Board of Examiners License #120-1, Class 1

Dominican Republic

PAGE 140F23

.,. ,-,:

004808

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc.

' fR0FESSI0NAL MEMBERSHIPS AND AFFILIATIONS (PAST AND PRESENT)

AslOCiateS of Clinical Pharmacology

AcupUnCtUre Academy of Oriental Medicine (Fellow)

A,ner1can Association for the Advancement of Science

Amerfcan Association for Clinical Chemistry §peclalty Division Membership o CDnlcal and Diagnostic Immunology Division o Nutrition DMsl~:-i o Uplds and Llpopids Division o Molecular Pathology Division

Ameriean College of Naturopathy

American College of International Physicians

American Holistic Health Sciences Association

American Nulrltlon Consultants Association

American Nutritional Medical Association (Fellow)

British Guild of Drugless Practitioners

Food and Drug Law Institute

Hahnemann Medical Society of America (Fellow)

International Bio-Oxidative Medicine Foundation

International Academy of Nubitional Consultants

International Rehabilitation Medicine Association

International Alliance of Nutrimedlcal Associations

International Society of Clinical Oncology (Fellow)

International Society of Internal Medicine (Fellow)

International Thermographlc Society

National Academy of Research Biochemists

National Academy of Thermology

Society for Nutrition and Preventive Medicine (Fellow)

U.K. Homeopathic Medical Association

·,

PAGE 15 OF 23

I •• I ''. I

0048nA

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 160F23

jjCTURES PRESENTED *

March 1992 - March 1993

March 1992 - March 1993

January 1993

1992

1989-1991

1988

August 1987

February 1987

May 1986

1985-1986

1984-1986

Oncology - Immunology Seminars and Tutorials Presented a series of lectures and training sessions to the main hospital physicians at Centro de lnvestigaciones Medico y Quirurgica (CIMEQ) Havana Cuba

Pharmacology I / II and Advanced Taught a series of pharmacological courses for physicians with clinical applications UFHEC - Schoo~ of Medicine, Dominican Republic

Advanced Oncology for medical residents Dominican Republic

Advanced Oncology UASD - Dominican Republic

Guest Professor at various medical colleges In Caribbean

Internal Medicine / Immunology / Oncology Lectures throughout the Caribbean

Featured Speaker at the First International Congress on Alternative Medicine (Government Sponsored)

Special Guest Appearance on Or. Arnold Pyke Show (Nutritional Show aired throughout the USA) Los Angeles, California USA

Lecture In Recent Advances of lmmuno-Oncology National Museum of History, Dominican Republic Lecture to Oncologists, Hematologists, Internists and medical students on recent advances

Lectures in Eclectic Medicine (monthly) for physicians through British West Indies Medical College, B.W.I.

Guest Lecturer at various medical conventions (Both traditional and alternative)

• Lectures presented after December 31, 1993 are in the ~ Additions Section" 004808

I

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 170F23

1980-1985

October 2, 1984

July 1984

May 12-13, 19M-

April 1984

1983-1984

December 1983

November 25, 1983

0dober1983

March 17, 1983

February 17, 1983

January 11, 18, 25 & February 1, 1983

Guest Appearance on radio and television shows dealing with health (Florida, Hawaii USA and in Europe)

Miscellaneous health lectures throughout the USA and Europe

High 12 Club New Port Richey, Florida USA

Hawaii Cancer Society Oahu, Hawaii USA

International L~cture on Research Data of Catalyst Altered Water Loma Unda University - Loma Linda, California USA In relationship to cancer therapy

First International Conference of the International Institute for Research on Metabolic Disease and Cancer Orlando, Florida USA

Fountain of Youth International Ft. Lauderdale, Florida USA Lecture on cancer and aging

Monthly lectures given to physicians as part of continuing education. Program in Nutritional Medicine

International Health Farm Miami, Florida USA

National Health Federation Deland, Florida USA

International Lecture on Research Data of Catalyst Altered Water Orlando, Florida USA - Cancer Research

New Smyrna Beach Rotary Club New Smyrna Beach, Florida USA

American Business Women's Association New Smyrna Beach, Florida USA

Community Health Lectures New Smyrna Beach, Florida USA

CURRICUL'UM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 18 OF 23

December 10, 1982

March 8 -12, 1976

November 19, 1975

November 11 - 14, 1975

June 1 - 4, 1975

April 17 -19, 1975

April 1975

November 21 -23.i 1974

November 20 - 23, 197 4

November 197 4

Aprll 19 -20, 1974

Aprll 5-6, 1974

University of Central Florida Orlando, Florida USA

Fifth Annual Workshop on Radioassay San Diego, California USA

International Academy of Sciences Indiana Academy of Sciences - Indiana State University Terre Haute, Indiana USA

:The American Society for Cell Biology San Juan, Puerto Rico (Workshop)

The Molecular Biology of Hormone Action, 34th Symposium of the Society of Developmental Biology University of Maine Orono, Maine USA (Workshop)

Midwest Regional Developmental Biology Conference Illinois State University Normal, Illinois USA

National Convention of Sigma Zeta Science Honor Society Missouri Valley College Marshall, Missouri USA

American Society for Cell Biology San Diego, California USA (Workshop)

American Society for Cell Biology San Diego, California USA

International Academy of Sciences Indiana Academy of Sciences, Purdue University West Lafayette, Indiana USA

Midwest Regional Development Biology Conference Eastem Michigan University Ypsllantt, Michigan USA

45th Annual Convention of Sigma Zeta Science Honor Society Baptist College Char1eston, South Carolina USA

004808

. ·~

j • '{

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. .PAGE 19 OF 23

EDITORIAL ACCOMPLISHMENTS

Primary Author of approximately 26 articles and Co-Author of others..... Most primary papers were in cellular biology, biochemistry and immuno-oncology ..... Also authored a manual entitled: Clinical Endoainology and Laboratory Medicine and co-developed an lmmunotherapy Protocol for physicians in the treatment of immune disease i.e. cancer, viral disease related to white cell dysfunction

Caplinger, G. E.

Caplinger, G. E.

Caplinger, G. E.

Caplinger, G. E.

Caplinger, G. E.

Caplinger, G. E.

• Caplinger, G. E.

Caplinger, G. E.

Caplinger, G. E.

Caplinger, G. E.

HIV / AIDS: Augmentative Therapy Utilizing An Immunological Approach October 1993

Progressive Immunology (Textbook of Immunology for residents, fellows ~md graduate students) B.W.I. Medical Press, June 1993

Physician or Scientist (A commentary on modem medicine) Manuscript, February 1992

lmmuno Therapy - Treatment of the Future B.W.I. Journal of Medicine, September 1991

Treating the Rheumatoid Patient B.W.I. Journal of Medicine, March 1991

A Practical Approach to Allergies Manuscript, November 1990

HIV/AIDS: A Proposal For Successful Therapy and Subsequent Remission August 1990 .

Effects of Biological Response Modifiers and Nutritional Supplementation In Patients with Various Types of Cancer In an Attempt to Reactivate Complete Immune Response May 1990

The Utilization of Amino Acids in the Treatment of Chronic Degenerative Disease March 1988

lmmuno-Therapy As Primary Therapy May 1990

f' CURRICULUM VITAE I ' 1 GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE 20OF23

cap1nger, G. E.

Pttard -Caplinger

cap1nger, G. E.

Caplinger, G. e.

Caplinger, G. E.

Caplinger, G. e.

capDnger, G. E.

caponger, G. e.

C8plinger, G. e.

Caplnger, G. e.

Clinical Endocrinology and laboratory Medicine (1l1is is a laboratory manual to be used in medical school and post-graduate studies) British West Indies Press, 1987

lmmuno-Therapy Protocol Physicians Manual, December 1986

Naturopathic Approach to Disease and The Utilization of Herbs, Dissertation for Doctor of Naturopathy Anglo American Institute of Drugless Therapy August 1984

Amino Acid Patterns in Cancer and Metabolic Integrity with Cellular Cooperation in the Immune Response; Proposal of an Alternative Treatment for Cancer - Dr. of Science in Biochemistry M.C.B.C. Institute, Great Britain, July 1982

The Development of Medicine as it Relates to Health Systems of Great Britain and the United States and The Preventive Medicine Trend Doctor of Medicine Dissertation, July 1982

Effects of Varied Mestranol Levels in Combination ... on Rat ovary J. of Dev. Biology, P. 8, 1975

Catalysis of an Allosterically ... In ovarian Metabolism International Academy of Sciences Proceedings 1975

Catalysis of an Allosterically ... In ovarian Metabolism The Journal of Cell Biology, P. 55, 1975

STH Maintenance In Hypophysectomized Rana Plpens with a Synergistic Affect The Sigma Zetan, P. 47, 1975

STH Maintenance In Hypophysectomized Rana Plpens with a Synergistic Affect The Journal of Cell Biology, P. 49, 197 4

004808

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc.

REFERENCES - PROFESSIONAL ....

American Biographical Institute Dr. Thomas J. Winters Mr. Michael Bland Dr. Homer Paschall Dr. Larry Gamion Mr. Roger Hooban FDOC Sussex General Hospital

REFERENCES - ACADEMIC

Bruce Copen, Ph.D. Dean - Sussex College of Technology Sussex,U.K.

Larry Gamion, Ph.D. Professor of Physiology Research Advisor Ball State University Muncie, Indiana USA

Thomas J. Winters, M.D., Ph.D. M.C.B.C. Institute Medical School Professor London. U.K.

Others upon request

REFERENCES - INSTITUTIONAL/ORGANIZATIONAL

Sussex General Hospital England, U.K. Jona1han Wainright. M.D.

British College of Physicians and Surgeons England, U.K. Jonathan Wainright, M.D.

- See attaehed letters. others upon request

PAGE 21 OF23

., ' 004808 :t

- - ---- ____ .c;:-__ ~=--------· ---·--· _,.,......,._ - ·- - - ~--------~------

.:/ :,·: -~, :~1i,~~k!.~tf ~:~;~1ttf:)i~• i

CURRICULUM VITAE

:;REGORY EARL CAPLINGER, M.D., D.Sc.

\4AJOR HOSPITAL/ CLINICAL AFFILIATION{S) -3r1tiSh West Indies Medical College Hospital and Clinics cnca Hispanoamericana

PAGE22 OF23

Dominican Republic Chief of Oncology/Immunology for all associated hospitals and clinics in U.K., USA and Caribbean 1982-Current

Hospital Dario Contrearas Santo Domingo, Dominican Republic Oncologynmmunology Consultant

Sussex General Hospital Sussex, England U .K. Chief of Staff 1982 - 1988 Chief of Oncology / Immunology, 1985-Current

Florida Degenerative Disease Center Florida, USA Chief of Consulting Staff for Oncology / Immunology 1985 -Current

Delaware International Hospital Wlmlngton, Delaware USA Chief of Consulting Staff for Oncology / Immunology 1990-1992

00480~

CURRICULUM VITAE

GREGORY EARL CAPLINGER, M.D., D.Sc. PAGE230F23

ADDITION(S) / CHANGE(S)

As there are changes from the original Curriculum Vitae they shall be added in the respective categories in the amex section (Continuing Education, Publication and Positions)

ENCLOSURE(S) (Attached Is a compilation of key articles)

Copy of Articles

1. lmmuno-Therapy As Primary Therapy

2. The Utilization of Amino Acids in the Treatment of Chronic Degenerative Disease

3. Effects of Biological, Biological Response Modifiers and Nutritional Supplementation in Patients with Various Types of Cancer In an Attempt to Reactivate Complete Immune Response

4. HIV/AIDS: A Proposal for Successful Therapy and Subsequent Remission

NO PART OF THIS CURRICULUM VITAE MAY BE COPIED OR RELFASED TO A

THIRD PARTY WITHOUT THE CONSENT OF THE AUTHOR. RELFASE OR

TRANSMITIAL OF SUCH IS A VIOLATION OF PRIVACY AND MAY RESULT IN

VIOLATION OF CRIMINAL LAW(S) AND THUS BE PROSECUTABLE

004808

CURRICULUM VITAE OF

GREGORY E. CAPLINGER, M.D., D.Sc.

PRIMARY/ IMPORTANT CERTIFICATES AND HONORS

Endosed are some of ttle main honors I certificates. others are noted in ttle body of ttle Curriculum Vitae.

-- - - --·----- -~=.-:.';:.....:::;;-:;:-«.'..'~-~--...-~~~-=-_;__~ -=·--==-~-=-..=-- -------------------- - -~

~ . - . ~:/ . ... ·: . ~

0 C) .p.. CX> C)

o:>

ilo~tor of t~C~ Year ~ ward . . .

l11 boqor or t.qc dcvotioQ, loynlt.y, uqd cqdlcss hours or work for tl}c ~.'N.1\l.~. nQd tl}c advar,cCillCQt, or the Nutrimedicul zmd ~lterr,ntive Healtb Care Systems aqd Pbllosopby, tbc i>cpartme11t or 'Nutrimcdicul Services or tbe ~.N.M.~. bcreby awards tqis cert.Uicnte or qoqor to

Gregory E. Caplinger l11 t.cstiII?or,y of tqc above statell)eQt, we qcrcby affix our sigI?atures aqd corporntioq seal to tqls documcr,t. <fills lpaviqg becq registered with our ~.'N.M.~. qatioqal office or, the / ,1t day of, bee. , 19 86 ~.i>.

~warded b] lbc 'i\.N.'?11.'i\. 'Dcpar1111c111 or 'Nulrl111cd1e~1 ~n-lc:1111 'P.O. -Box •5?-15, 'Pboc:11l1, 'i\Z 85060

'lHrcctor

·;. J1wc tu. ofluJn,'7 ¾· 'A.N.'!\1.'A. 'Registrar

~nweuuk~ <GK~ rr»~ Q/~ er <OH«u:druY

~enudav rev~~ 0/~f"V

QJ,f'r4rr ~a,u,e/1/--~ ry-~vv er~, ~le-,a,dW~«vl/h,~ ~ .

<<:§.,,,,~ ce~&rrev. <?:»t. QJ., q,~ ~­w~ o,1 c:e~ ~~

~c?ltf#~01t''o/'~- ~~- QJ. ~ ,.Ji#,~ c/~ <"Gft,rk-d~~­~ ~~ ~~~~,ti/. /986, ,o.-_oo w. nv. ~ ,2.-00 nv.

~~':>/ de,~w.re,,Y~ ~

f?4trvJ;~~~, 9'~~02l',wra)Q/~

<,laf'~rtJ~. ~,,,uf+'r/)°""°~ ---·. :.:;;· ·-- -~-~--' ___ ·. - .· .. .--: --".'"·-:.'?.J/\r· .. ~::-: . :_ ·, 004808

.:~

INTERNATIONAL INSTITUTE FOR RESEARCH

ON METABOLIC DISEASES AND CANCER

THE OBJECTIVES AND INTERNATIONAL STATUTES

The lntemational Institute for Research 011 Metabolic /)iseases and Cancer was founded in Lisbon by Dr. Serge Jurasunas the actual chairman. During a visit of Dr. Clark in Lisbon both decided to give a wider dimension to the Insti~ute by planing a seminar in Florida where headquarters were to be established. The creation of the Institute and the seminar was also possible in view of the international support that Dr. Jurasunas received from researchers and doctors like Bradford, Rodriguez, Oswald, Bock and others who became members.

CANCER is not a disease but a self destrnction of the entire system whose mechanism exists in everyone of us.

SERGE JURASUNAS

Chairman

Vice-chairman

Secretary

Board directors

SERGE JURASUNAS N.D. - Ph. D.

DANIEL CLARK D.H.M.

MARIA LUCINDA TAVARES DA SILVA

ROBERT BRADFORD Ph. D.

RODRIGO RODRIGUEZ M.D.

GREGORY E. CAPLINGER M.D.

HENK OSWALD M.D. (Hom)

SIEGFRIED W. BOK M.D.

A - OUR OHJECTIVES

H - THE INTERNATIONAL STATUTES

C - THE WELCOME FROM TIIE FOUNDING CHAIRMAN

D - THE INTERNATIONAL HOARD COMMITTEE

r

GREGORY E. CAPLINGER, M.D., Ph. D.

Member of the board co111mittee

Dr. Caplinger is presently practicing as a homeopathic physician in the United Stales of America. His training is one of British back-ground in medicine with Ph. D. training in biochemistry. In the past he has taught medical courses lo nursing students and medical students in the United States. fie is Director of a research project at Ball State University in ovarian metabolism (protein chemistry). He is president and founder of the institute of Holistic Medical Research of which the main purpose is research in chronic degenerative disease and alternative treatments. He has just received board certification in homeopathic internal medicine from the flahnemann Medical Society. He is presently doing post graduate studies in internal medicine through Harvard. Dr. Caplinger is also a member of many homeopathic and preventive medical societies OJld associations of which he is a fellow in many of these.

004808 . ·. : :· .. ::: -~ - --- ----- ----- --- - -- -- --=--=-- -- ----·-~- ·-----· __ ......,. ~- - -- -

. '

.·~

9:00 a.m.

9:30 a.m. • 10:30 a.m.

10:30 a.m. - 12:00

12:00 • 1:30 p.m.

1 :30 p.m. - 3:00 p.m.

3:00 p.m. • 4:30 p.m.

9:00 a.m. - 10:30 a.m.

10:30 a.m. - 12:00

1 :30 p.m. - 2:30 p.m.

2:30 p.m. - 3:30 p.m.

3:30 p.m. - 4:30 p.m.

4:30 p.m. - 5:30 p.m.

5:30 p.m.

PROGRAM AGENDA

SATURDAY, MAY 12, 1984

Opening Remarks Professor Serge Jurasunas

"Herbal Poultices as AdJunctlve Thereapy In the Nutritional/Metabolic Nutritional/Metabolic Management of Cancer"

/•Amino Acid Applications In Cancer and Chronic Degenerative Disease"

Lunch

"Germanium, Blocalalysls and other Modern Approaches to Cancer"

"Ozone: It's Therapeutic Action"

SUNDAY, MAY 13, 1984

"Early Warning and Prophylactic Systems -(EWAPS) - In the Medicine of the Future"

"lntergratlng Nat1Jral, Non-Toxic Therapies In Cancer and other Degenerative Diseases"

"Electroacupunclure Applications In Cancer and Chronic Degenerative Disease"

"Hot Herbal Baths as Adjunctive Therapy In the Nutrlllonal/Metabollc Management of Chronic Degenerative Diseases"

"S.J. Therapy In the Treatment of Degenerative Diseases and Cancer"

/ "Scientific Basis ol Alternative Cancer Therapy"

'

Daniel Clark, M.D.

Gregory Caplinger, M.D., H.M.D.

Prof. Serge Jurasunas

GeNge Frelbolt, H.M.D. N.D.

Robert W. Bradford

Rodrigo Rodriguez, M.D.

John Milovich, N.D.

Daniel Clark, M.0.

Gerard Serry, M.D., H.M.D.

Gregory Caplinger, M.D., H.M.0.

"The Use of Bloelectrometer In the Detection of Cancer" Prof. Serge Jurasunas

004808

.,

HARVARD MEDICAL SCHOOL CONTINUING EDUCATION

DR. GREGORY CAPLINGER

'

E.

HARVARD MEDICAL SCHOOL DEPARTMENT OP CONTINUING EDUCATION

BosToN, MASSACHUSETTS

THIS JS TO GER TIFY THAT

Gregory E. Cap I inger

was enrolled in the Department of Continuing Education of

Harvard Medical School for the cour.se entitled

CANCER MEDICINE September 14 - 18, 1987

Harvard Medical School i.s accredited by the Accreditation

Council for Continuing Medical Educati'on (ACCME) to

sponsor continuing medical education for physicians.

This offering meets the criteria for 38 credit

hours in Category 1 of the Physician's Recognition Award

of the Amen·can Medical Association.

004808

.

,_._,i_•ji:

I :1.

:it 'il :t! :i; I·

!!

,1:

.I-! ct• . i

,ii r;

'I ;·",'

i,

• HARVARD MEDICAL SCHOOL

DEPARTMENT OP CONTINUING EDUCATION

DosToN, MASSACHUSETTS

THIS IS TO CERTIFY THAT

Gregory E. Captlnger

was enrolled in the Department of Continuing Education of

Harvard Medical School for the course entitled

PRIMARY CARE INTERNAL MEDICINE November 9-13, 1987

Harvard ·Medical School is accredited by the Accreditation

Council for Continuing Medical Education (ACCME) to

sponsor continuing medical education for physicians.

This offen·ng meets the cn·tena for 38 credit

hours m Category 1 of the Physician's Recognition Award

of the Amen·can Medical Association.

'1 !I 'il )•·,

-

Sussex College of Technology Sussex • England

It is hereby certified that

GREOORY EARL CAPLINGER. M D. D. Sc.,

having passed examinations in

m.t>LETIOO OF A FVTA11N3 SYSTEM IN INTERNAL NEDIQN: Wint Eltt'HA,gS IN CLINICAL OOOOLOGY &DtM.H>LOOY .

( 1984 • 1987 )

as prescribed by the Faculty of this College, we have registered the above named, under the regulations governing the educational standards of this organisation,

and assigned the

CERTIFICATEOFfXM>LETION

together with all rights, honours and privileges pertammg to the award. In testimony whereof we have issued this Diploma signed by our hands and

affixed with the Seal of this College

this __ .__;~ ___ day of DECE1teER in the year_ 1987 ______ _

Dean of the College Registrar

~,,,.~ Secretary

-Lia ?--Q, -aj o o 4 a a a

-~ ·.-

e?nqtand

GREGORY E. CAPLINGER M.D. ------bas bun ahtarbtb tbt .bistindian af

--···· .. ····· .. ·························-········· .. ··· .. ········ .... LIFE .... FELLOW ............................................................. --

fagtfbtr fuitb all rigbts, barumr.s anb bignitv ptrlincnt tu tbt atnarb, in rtrognitian af inttlltdnal anh stubi1T1ts ahilitJ1. ffl;bt tltgtnts 1lf tbis Qt111lc9c issu.e tbis Qttrtiftratt in

a,knatultbgtmtnf tbis. ............ J.lh ............... bav uf .................... AY9..Y.~!. .......................... in tbt }ltar 1992

004808

Metropolitan Collegiate Institute BC M • Collegiate,

London we, N 3XX, England.

Dean: J.T. Stratton Ph.D. M.A. Registrar: Michael S. Bland B.Sc.

August 20, 1984

To Whom It May Concern:

I am writing regarding Dr. Gregory E. Caplinger. He was a student / graduate of our institution from 1979 - 1982 with completion of the Doctor of Medicine (MD}. He did further studies coordinated here in the UK and by ourselves and Sussex College of Technology leading to a specialization certificate in Internal Medicine with subspecialties in the areas of oncology and Immunology.

While a student, Dr. Caplinger was at the top of his class and he demonstrated clinical and scientific ability that is worthy of great honors now and in the future. He was lmown by professors and students as a man of integrity and extreme brilliance - not afraid of being different.

He comes with the highest recommendation!

Clas·s Position: 2 Class Size: 36

Sincerely,

Stratton, Ph.D. DEAN

P.S. our Institute due to the "Educational Reform Act of 1988" has ceased to function. However, archives are maintained at: Medical College 7-11 Kensington High Street London we SNP England

j:·

BALL STATE UNIVERSITY MUNCIE, INOIANA 47306

COLLEGE OF SCIENCES & HUMANITIES Department of Physlology and Health Science

TO Whom It May Concern:

June 13, 1985

This is a letter of reference to support the application of Gregory Caplinger.

Greg was enrolled as a graduate student at Ball State University during the 1975-;S academic year. He was a student in my human embry­ology course and received a course grade of B. Greg was also a graduate assistant in our department and provided instructional assistance in our basic human anatomy and physiology courses. Further he was active in research and examined the mechanism of mestranol action on ovarian metabolism. Some of this work was reported at regional and state meet­ings.

LG:jl

In closing I recommend Greg to you.

Sincerely yours,

'cl ~~ Lar~~on, Ph.D. Professor of Physiology

and Health Science

Ball Stale Unlverwlt, la on equal oppoitunlt, employer 004808

BALL STATE UNIVERSITY MUNCIE, INOIAHA ,7306

COLLEGE OF SCIENCES & HUMANITIES Department of Physiology and Health Science

To Whom It May Concern:

June 13, 1985

This letter is in support of Dr. Gregory Caplinger. Dr. Caplinger was a graduate student at Ball State University in 1975 and 1976.and had a major in physiology. For much of the time he was at Ball State he had a graduate assistantship in the Department of Physiology and Health Science. Most of his responsibilities consisted of working with students in the laboratory. He appeared to enjoy working with students. He related well with them and knew the material well. Dr. Caplinger was a person of high moral standards.

I have not had much contact with Dr. Caplinger since he left Ball State University, but believe he should be given serious consider­ation for employment.

HDP:jl

Sincerely,

L~fkrto. Professor of Physiology and

Health Science

Ball Slat• Unlverall)' la on equol opporlunlly employer 004808

I .1

AB/ American Biographical Institute, Inc.

Publisher of Biographical Reference Works Member of the Association of American Publishers, Inc.

Main Oltice: 5126 Bur Oak Circle, PO Box 31226. Raleigh. Nonll Caroline 27622 USA • Ellablislled 1967 • ISBN Prel11t 934544

May 29, 1987

Dr. Gregory E. Caplinger

Dear Dr. Caplinger:

Your name has been recommended to the lnstitute's Governing Board of Editors for biographical inclusion in the Second Edition of the INTERNATIONAL DI­RECTORY OF DISTINGUISHED LEADERSHIP. This recommendation was brought to our attention through the personal nomination of Dr. Thomas J. Winters.

The enclosed brochure provides you with information about this prestigious volume and the commemorative awards which are made available to you for specifically recognizing your outstanding achievements. Although purchase is not a prerequisite for inclusion and there is no fee for listing, you may want to take advantage of the special pre-publication prices we as the publisher are able to offer.

I look forward to hearing from you by the date indicated on the brochure and I congratulate you on the fine example you are setting. My best wishes for all your future endeavors.

Respectfully,

J. M. Evans GOVERNING BOARD OF EDITORS

JME/hcw

Enclosures

004808

,!

.;I f

Ball State University ..

College of Sciences and Humaniti~ Department of Physiology and Health Science

Dear Mr. Banner:

April 21, 1988

This letter is in response to a request made by Gregory Caplinger to send you a character reference and a report concerning the classes he took at Ball State University.

Dr. Caplinger was a graduate student at Ball !:>cate University in 1975 and 1976 majoring in Physiology. For much of the time he had a graduate assistantship in the Department of Physiology and Health Science. Most of his responsibility was that of being an assistant in the basic anatany and physiology laboratories. He appeared to enjoy working with students, related well with them and knew the needed material well. In his time here, he canpleted four quarter hour graduate courses in human embryology, biochemistry, mammalian physiology, cellu­lar physiology, biophysics, advanced topics in chemistry, fundamentals of patho­logy and bioethics. He also did four hours of special studies and one hour of seminar.

As I recall, while he was a graduate student, he became heavily involved in a church ministry and felt that this was the direction he should go in life. There was not enough time to do both so he finally stopped working on his thesis.

Since that time, I have had very limited contact with Dr. Caplinger. I trust that this.infonnation will be helpful • •

bk

Sincerely yours,

~~ Professor of Physiology and

Health Science

Charles R. Carroll Acting Chair, Physiology and

Health Science

004808 lli-~S;-5%1 Muncie, Indiana -¼7306-0il0

'j

'

FLORIDA DEGENERATIVE DISEASE CENTER

02 January 1992

Dear Sirs:

I am writing to recommend Dr. Gregory E. Caplinger. I have personally known Dr. Caplinger as a student, in which I served on his dissertation committee, and as a colleague.

In both capacities, student and colleague, he has proven to be a tremendous person end a superb physician. It is without hesitation I recommend Dr. Cap · ger.

1323 Sourn STA'JE ROAD 7, #436 • NoRrn LAUDERDALE, FLORIDA 33068 • 0 0 4 8 0 8 ______ _.;;... _______ ;...._ _______ _ (A DMSION OF B.W.I.M.C.)

SVSSPX qE,gyr£(JlJL£ 1fOS<PI<f.Jl£ SVSSPX!M!ElDICJlL (JF,!NJJlfP, L'IJD

March 1, 1994

Dear Sirs,

Currently Dr. Caplinger serves as Chief of Imm.wio-Oncolo~. In the pa.st he al.so completed hi.s various aspects of training under our directions.

We fully, without hesitation, recommend him for whatever position.

Profes!'3ionally,

Jonathan Wainright, M.D. Chief of Staff

004808

CURRICULUM VITAE OF

GREGORY E. CAPLINGER, M.D., D.Sc.

REFERENCE ARTICLES

PRIMARY RESEARCH ARTICLES

The articles enclosed are 1hose of major significance. others are noted In the body of the Curriculum Vitae.

004808 ~~~------ ----------- ---- ..... --- .

Program of the

FOURTEENTH ANNUAL MEETING of the

AMERICAN SOCIETY FOR CELL BIOLOGY

Noveniber 20-23, 1974

San Diego, California

Com1nunity Concourse

PHOGHAM COMMITfEE

HELEN A. PADYKULA (Clwirn1a11) NELSON FAUSTO SUSAN A. GERBI DANIEL A. GOODENOUGH OLGA GREENC,\RD SANFORD PALAY THOMAS D. POLLARD CARLOS SoNNENSCHElN HAYMOND E. STEPHENS HOBERT L. TRELSTAD

LOCAL AHHANGEMENTS

SILVIO VARON (Cl1air111a11) lhcHARD FJRTEL and WILLIAM Lool\ns: Social Ei·c,its STEVE HowELL, UAllfON PINON and WILLIE BRowN:

P11blicity 6r P11blic Program l\lURIEL NESBITT and RUTH KAVENOFF: Str,dcnt Mo11itors CHRISTOPHER W1LLS, b.1Mo SCHEFFLER and

DoucLAS SI\UTH: Logistics, cqrtipn,ent a11d poster sesiio11s

- -----------. ~~ ..

)

/ ,. .

004808

E. Lazarides* o: Boulder, Co. le microtubule lyethylene glycol ( Can de et a 1. •

in tubulin is in PEG solutions, to-pole and 1, the chromosones ·face is pitted, extensively ire extensively iunding cytoplasm igmented. Cells to some low molec-but not alter

o fall apart with­s the spindle tubulin (<10mg/

ls or in cells il 1 not move a 11 ctin, anti-11\YOSin, in they are includ­inti-actin and S1 md act in- H ke >Ut there are no :ed with anti-les are stained.

DERMAL MITOSIS lecular B1o­Augusta,

, epidermal t'S in the G2

1n the control th cAMP and totic activity

:t on the in-t in the cul-3. Equivalent 1ce on the 1n-1mber of col­;;ystam has no 1g 1nh1 bi tion 1yll1ne, an

1y fqr 32, effect during

lled DNA. pre­li'irmed that i of the cell 'f on cut in-

97. STH MAINTENANCE IN HPOPHYSECTOMIZED RANA PIPENS WITH A SYNERGISTIC lFiECT Gregory E. Caplin~er.• Department of Z.Oology, Anderson College, l1jerson, Indiana. (Intro uction by Marie J. Mayo)

Hypophysectomization of an adult Rana pipens with a variable STH :a1ntenance program produces various effeciency levels of the endocrine )7~te~ which in turn affects the metabolism of the frog. With the t~ployment of dosages of STH along with the injections of Follicle .m111ulating Hormone (FSH), Leutenizing Hormone (LH), Thyroid Stimulating ::;;mone (TSH) and Melanopore Stimulating Hormone (MSH), a hormonal e1~ilibrium is produced in varying'degrees which also aids in establishing 1 i::etabolic equilibrium. STH used concurrently with FSH, LH, TSH and MSH JU increase the overall rate of function in the hypophysectomized frog in 111 instances except after fifteen days post-operative in which a relatively )~.all dosage was employed. With an alteration of the dosage level and time 1:tervals a fairly stable metabolic equilibrium may be established. Upon ,tservation some injection intervals and dosages produced very little if •~-'J type of hormonal and consequently metabolic equilibrium. In dealing 1,itn amphibians and the B!!!!i pipens in general one must quantitate the :ttabolic equilibrium in close conjunction with the hormonal equilibrium a:J thus a maintenance program for the hypophysectomized animal may be t~tablished. The best means for establishing a quantitative set of data is

t;i take a Basic Metabolic Rate reading on the animal and from this reading ,:u also measurements of hormonal output a direct correlation can be made :ct;.-een a metabolic equilibrium and a hormonal equilibrium. Thus unless t:.ure is a fairly constant now of hormones within the endocrine system the ur1ous target organs may atrophy and become non-functional. Extremely hr 6e dosages may maintain equilibrium but the long term effect may result ln irreparable damage to the target organs affected. The results have i:.:.;rn that employment of STH alone will not affect the metabolic equilibrium. ::.~~ .:ifH in hypophysectomization is the key biological synergist.

9& ULTRASTRUCTURAL LOCALIZATION OF CALCIUM IN IJHFERTILIZED SEA URCHIN ICCS Constance Cardasis*, Herbert Schuel and Lawrence Berman. Department of Anatomy, Biochemistry and Pathology, Downstate Medical Center, s.u.N.Y., lroollyn, N.Y. .

Calcium ions have been :Implicated in the coupling of excitation to acUvati~n of many cellular processes including fertilization, secretion, ate. Unfertilized, ovulated Strongylocentrotus purpuratus eggs were fixed lo aea water containing gluta-raldehyde and post fixed in 0&111ium-pyroantimo­ut1 (Spicer, et. al., J. Cell Biol. 22:697, 1968). The latter antimonate 111p binds cations generally and when used in conjunction with X-ray, · 1lcroprobe analysis (Berman, et. al., J. Ultraatr. I.es. 42:298, 1973) or with ethyleoeglycol-tetraacetic acid (EGTA) can serve to identify calcium. Dtpolita of ant:lmonate were observed on the membranes of the cortical 1r1nulea and yolk platelets and on the plasma membrane. These deposits were rarely observed on the membranes of the cortical granules and yolk tlateleta and reduced in number on the plasma membrane of eggs fixed in calc1111 free sea water containing a specific calcium chelator, EGTA. S. T. I.It, - X ray microprobe analysis (Stereoscan microscope; cmputor assisted WI solid state detector) confirmed the presence of both calcium and utlmonate at these cytoplasmic locationa.* These results suggest that ulcl11111 iooe preaent in the plasma membrane, and the membranes of the cortical granules and yolk platelets in unfertilized sea urchin eggs may t1rticlpate in the function of these organelles at fertilization.*Courtesy af Dr. E.W. Dempsey, Dept. of Anatomy, Columbia Univ. College of Physicians aa.t Surgeons. (Supported by grants CA-06081 from the National Cancer &111tltute 1 P-616 from the .American Cancer Society and M74.034 from the fapulation Council).

AbatTGd1 F~h,Annual Jleding .hnerican Socidy for Cell Biology 49 a

004808

.:~

VOLUME 67 NUMBER 2 PART 2 · NOVEMBER 1975

Abstracts· FIFTEENTH ANNUAL MEETING oF

THE AMERICAN SOCIETY FOR CELL BIOLOGY

El San Juan Hotel, San Juan, Puerto Rico, 11-14 November 1975

TI-IE JOURNAL OF

(.' 1 . . ....

l I • . I

' I 1 ! I\ ~

. l I I

•I

','.

J -ll~J ·n ·

ii J

-- ·- -----·-·--•-·---------·--

PUBLISHED BY THE

ROCKEFELLER UNIVERSITY PRESS

NEW YORK

JCLBA3 67 (2, Pc. 2) l a-483 a (1975) ISSN 002l•S'525

'·• ·,.· ..

. /,.i, .. ·•.11.: .• :-_ . __ ... ··.;.:·: .

. ---- __ ...,.,___ --"'1!.;:>1"ef!f':idf~t~• .. ~~ ':2~•" · ifo'.,-: ~~~~'$; ·'·~~:<,. -- -', < ~~·c.:. '.:-_~:

r-

t-

y.

n,

1r

/ 1119. CATALYSIS OF AN ALLOSTERICALLY INHIBITING NUCLEOTIDE WITH A SYNTHETIC ESTROGEN AND A SUBSEQUENT ALTERATION IN OVARIAN METABOLISM Greg Caplinger.• Dept. or 1.oology, Anderson College, Anderson, Indiana. (Intr. by Marie Mayo)

The ovarian synthesis of proteins may be subject to amino acid alterations as a result of the treatment with synthetic estrogens. Wistar white adult fe­ule rats were given intramuscular injections ot a synthetic estrogen com­pound known as Mestranol (1?-ethynylestradiol )-methyl ether) which was fol­lowed by the isolation of two dinstinct cell free ovarian proteins in both the experimental and the control groups. When looking at the biosynthesis of •~trogen one sees that NAD is needed in the conversion of cholesterol to 6 -pregnenolone. .Also it has been noted that NAD will allosterically inhibit LDH and thus decrease the LDH content. In the ovarian synthesis of estrogen ve found a very unique interrelationship in the metabolic scheme. First of all it was recognized that Mestranol injected in small quantities acted to catalyze the reaction involving NAD and thus an allosteric inhibition and a lower level ot LDH was measured. .Also the elevated level and catalysis of NlD resulted in the addition of amino acid residues to the two isolated ovarian proteins. With a subsequent use of a high quantity of Mestranol the NlD level was decreased, thus alleviating the allosteric inhibition of LDH. This decreased level of N.AD resulted in the deletion of amino acid residues from the two isolated ovarian proteins. From this unique metabolic scheme there has developed · the uncovering of a two way recognition mechanism. Cho­lesterol levels are not altered by the Mestranol alone but cholesterol recog­nizes the physiological estrogen in the normal negative feedback pattern and the levels ot Mestranol are recognized by NAD. In conclusion one can see how the injections of a synthetic estrogen have induced changed in the amino acid content without a subsequent change in the estrogen level. With a prolonged alteration in the amino acid content there will no doubt be an induced nucleotide alteration which will change the ovarian biosynthetic pattern.

I IO. MORPHOLOGICAL AND BIOCHEMICAL ANALYSES OF ULTRASTRUCTURALLY PURE ilASAL LAMINA ISOLATED FROM MICROVESSELS, RENAL TUBULES AND RENAL GLOMERULI EJvard C. Carlson, Elias Meezan*, Klaus Brendel*, Margaret Krasovich* and l'oiiilJJelle.* Departments of Anatomy and Pharmacology, University of Arizona College of Medicine, Tucson, Arizona.

Ultrastructurally pure basal laminae (BL) were derived from various organ subfractions by treatment with 4% sodium deoxycholate, wh~c_h solubilized cell umbranes and intracellular components. Since BL glycoproteins and collagens are insoluble in this reagent, the laminae remain intact and are ultrastruc­turally indistinguishable from their in vivo counterparts. Isolated BL are composed of fine fibrillar and flocculent amorphous materials. Striated collagen or elastic fibrils are infrequently observed. Retinal vessel BL averaged 300-500i in width, while similar materials from brain microvessels vary from 200-5ooi. Vessel diameter is unrelated to the width of its BL, but ultrastructural impurities are more common when larger vessels are used as a source. Renal tubule BL averaged 1200-2000i in width and appear as folded homo~eneous sheets. ·a1omerular BL are similar, but somewhat thicker (1500-2500X). BL exposed to collagenase (1% for 40 minutes) show uncharacteristic, indistinct surfaces and numerous fine fibrils in the adjacent space. Similar results are seen following trypsin treatment, and when this __ enzyme is employed for 24 hours there is a complete loss of BL integrity. Amino acid analyses indicate increasing hydroxylation of lysine or proline in vessel, tubular and blomerular BL respectively. Carbohydrate analyses show hexose concentrations vary slightly in different types of BL but that all glycosylated to a lesser extent than that reported for bovine lens capsule (Spiro, 1 69). Our data indicate that treatment of•dissociated tissues with deoxycholate is a useful method for preparation of ultrastructurally pure BL with sufficient yield for experimental work.· Furthermore, these studies show that isolated BL exhibit morphological and compositional tissue specificity which may be critical .to their function_al activity.',':i:.<\

:·: .' .. · . f · , . .._ .. .. : :/It ;'\(.<':i{W.l,;}< , .• .. •· .-,:.<;<::: · '.>: <',iAbstracu Fifteenth Annual Meeting American Sodety for Cell Biology 55 a

-·· \t::it(tr1-i/,.-· <,:;::: ._..·,•~:,-· .. ·;\};~{Wfifft{1Hf-.-.:.,,i,:i.,.:·· - -~------·------~-- - - - ~

I:-

•-~ "~

:ii

- -~-~-------. --- - .

·?~\tt,ir;,t,~i1f~ic~:,,~.,:i~~:Jf ~~i(~\10c - ,i

STH MAINTENANCE IN HYPOPHYSECTOMIZED RANA PIPENS WITH A SYNERGISTIC fFFECT

By Gregory E. Caplinger

Hypophysectomization of an adult Rana pipens with a variable STH maintenance program produces various effeciency levels of the endocrine system which in turn affects the metabolism of the frog. With the employment of dosages of STH along with the injections of FSH, LH, TSH and MSH a hormonal equilibrium is produced in varying degroes which also aids in establishing a metabolic equilibrium. STH used concurrently with FSH, LH, TSH and MSH did increase the overall rate of function in the hynophysectomized frog in all instances except after fifteen days post­opcralivf in a relatively small dosage. Altering the dosage levels and the time intervals a fairly stable metabolic equilibrium may be established. The various Josages and time intervals used produced data that gave observations that at certain dasages and certain time intervals post-operative, the use of STH and other concurrent hormones had little if any affect on a metabolic equilibrium. fhus unless there is a fairly constant flow of hormones within the endocrine system the various target organs may atrophy and become non-functional. Ex­tremely large dosa:es may maintain equilibrium but the long term effect may result in irreparable damage to the target organs affected. The results have shown that hypophysectomized Rana pipens endocrine glands are much like that of mammals in that employment of STH alone will not affect the metabolic equilibrium. STII used concurrently with TSH, LH, FSH and MSH may establish an equilibrium. rhus STH in hypophysectomization is the key biological synergist.

Ho, D. T. H. and J. I. Varner MSU/AIC Plant Research Laboratory, Michigan State University, I. Lansing, MI 48823

HORMOllAL COMTROL or Snttll!SIS or RIBOWCLIIC ACID COMTAINING POLYADIIIYLIC ACID IN BAR.LEY ALIURONI LAYERS

Ribonucleic acid with a covalently attached polyadenylic acid segment (poly A-lUlA) has been found in barley aleurone cells. Poly A-RNA can be separated from non-poly A-IUIA by ~iltration through a Whatman GP/C filter with immobilized polyuridylic acid. Poly A-IUIA is polydispersed in size and poly A segment, which contains more than 901 AMP, ia l~cated adjacent to the 3'-01 end of the molecule. Employing short term label with radioactive adenosine, we observed that gibberellic acid (GA3) enhanced the synthesis of poly A-RNA after.a lag period of 3-4 hours.· The enhancement reached a maximum (50-601 over control) at 10-12 hours after GA3 addition and decreased afterwards. Abscisic acid at 5 !!tl reversed the GA3 effect on p~ly A­RllA synthesis. The implication of increased poly A-IUIA synthesis for the hormonal control of enzyme formation in barley aleurone cells will be discussed.

This work was supported by the U. s. Atomic Energy Commission under Contract ~o. AT{ll-1)-1338.

JO

.a,.,-.::,.

- --- ---. . .. .. ~- '

0,04808

,, ,,

i

HIV/AIDS: AUGMENTATIVE THERAPY UTILIZING AN IMMUNOLOGICAL APPROACH

Caplinger, Gregory E.

ABSTRACT

Since the discovery of HIV/AIDS many researchers have been looking for a cure that deals directly with the virus. However, Caplinger et al. believes that the more positive results are in the discovery of a treatment/medicine that augments immunological function.

Therefore, the following article will discuss and review the results of an augmentative therapy utilizing a vaccine (ImmuStimO) and a concurrent immunologically stimulative parenteral protocol.

Further, the subsequent results in most if not all patients at least revealed an increase/improvement in the quality of life. This is not to sta~., that ImmuStimO is a cure but only an augmentative therapy to prolong and/or improve the quality of life.

INTRODUCTION

The major emphasis in HIV/AIDS therapy has been to treyt the virus with ant iretroviral agents and supportive therapy. However, scientifically most medical treatments that function to destroy (directly) the causal agent generally fall short due to: ( 1) toxicity - adverse effects due to drug strength and target, (2) lack of ability to maintain the causal agent due to rapid proliferation of the agent beyond the efficacy of the drug, and (3) inability of 'he drug to recognize and attack a mutant form of the causal agent.

One slightly overlooked or underestimated possibility is that of manipulation of the T lymphocytes by various drug agents and concurrent act ion ( s) by other drugs or combinations of such. Therefore, the protocol of Caplinger et al. consists of: vaccine which contains interleukin-2 (IL2), antioxidants, enzymes with effects on macrophagic activity, and agents to stimulate cell mediated immunity, humeral immunity, and general immune response. 1 •3•4 ·

The effect of stimulation of the immune system and those areas of immunity affected by the HIV are done in such a way so as to effect in a stimulative manner the cellular reactions as represented below

· (Type III/IV). Further, IL2 is known to be a strong and effective activator of T cells. Without the active T cells and macrophages, it is virtually impossible to have any significant effect in HIV/AIDS therapy. 6

004808

r ('

- 2 -

GELL AND COOMBS CLASSIFICATION OF HYPERSENSITIVITY REACTIONS

TYPEI

REACTIONS Anaphylactic (immediate, atopic, lgE• mediated, re­aginic)

TYPED

-''t'?'"'•··"":i·.

REACTIONS Cytotoxic (cyto­lytic, comple­ment-dependent cytolOXiclty)

Fe receptor ---

PATHOPHYSIOLOGY Binding of antigens to lgE antibodies on mast cell surfaces l'8lealle8 allergic mediators, causing vaso­ditalion, increased capil­lary penneab!Uty, smoolh­muscle contraction, and eosinophlfia.

. ~/·~· ~· ; .. .--. -· .... ·.(·_.·,~-fr.:<-~";

~l~}:

PATHOPHYSIOLOGY Binding of lgG or lgM anti­bodies to callular or exog-. enous anligen8 activates the complement cascade, resulting In phagocytoals or cytolyais.

• Va&octilation : . '·., .. '. ..

• Increased Y8SClllar: ,• ·.,: / . permeability ; ,. · ;. '., ,, •

~,=~~~,?E.:: / • Cellular infittratlon by ..

eosinophlls and 0

neutrophits_ o)i-·. o ~/o;_:o:~ ·_

oo ~o ... ·.·· Release of •. allergic medial011, .•. 0 ,. ·c:· ,·.,

SIGNS AND SYMPTOMS Systemic: angioedema; hypotension; broncho­spasm, GI or uterine spasm; stridor Local: urticaria, pruritus

SIGNS AND SYMPTOMS Varies with disease; can Include dyspnea, hemop­tysis, fever

,.·-'. .•,·•··:·.;',.

CLINICAL EXAMPLES Extrinsic asthma, sea­sonal allergic rhinitis, sys­temic anaphylaxis, reactions to stinging in­sects, some food and drug reactions, sorne cases of urticaria, infantile eczema

CLINICAL EXAMPLES Goodpasture's syndrome, aulOimmune hemolytic anemia, lhrombocyto­penia, pernicious anemia, hyperacute renal allograft rejection, transfusion reac­tion, hemOlylic disease of the newt>om, some drug reactions

004808

·:I '.-i

•

- 3 -

REACTIONS PATHOPHYSIOLOGY Immune complex Activation of complement disease by immune complexes

causes Infiltration of poly­morphonuclear leukocytes and release of ly&osomal enzymes and permeability factors, producing an In­flammatory reaction.

---·------

SIGNS AND SYMPTOMS CLINICAL EXAMPLES Urticaria, palpable pur• pura, adenopathy, Joint pain, fever, serum sick• ness-llke syndrome

Serum sickness due to serum, drugs, or viral hep­atitis antigen; membra• nous glomerulonephrltis; systemic lupus erythema­tosus; rheumatoid arthri­tis; polyarterilis; cryoglobulinemia

004808

-~~::~~?~f7~-iif;1;{·li~ijfif!t~f~? · . :. . :

- 4 -

The other aspect of the protocol utilizing (1) · amino acids, (2) support. The ref ore, it is the Caplinger et al. protocol to: 1

is that of parenteral therapy IL2/IL6, and (3) nutritional intent of ImmuStimC and the

A. Stimulate T cells and macrophages to destroy HIV.

B. Stimulate cell mediated humoral and general immunity/immune response.

C. Oxidize any existing free radical pathogens (FRP's).

D. Give the needed nutritional support.

E. Improve the general quality of life.

PROTOCOL

I. ImmuStim-vo Vaccine

o Given in doses of 0.10-0.25 cc SC 1-3 times weekly and then decreasing as indicated.

II Parenteral TherapY (IV)

o Amino acids 3 • 6-6. 0% ( Amino syn from Abbott) given in doses of 100 ml - 260 ml daily and then as indicated.

o Nutritional therapy which consists of:

D5W ) B Vitamins ) 100 ml given concurrently with the Vitamin C ) amino acids. Minerals )

Within the protocol the medical team must also discuss and address the issue of diet, exercise, and stress reduction to maximize the results. Further, 'the length of therapy initially is dependent upon the patient's CD4+ cells, CD4+ T lymphocytes, and general health condition.

To date therapy has been maintained indefinitely for maintenance of the patient. However, this is done less frequently and at lower doses.

- 5 -

DATA SUMMARY

THERAPY BEGAN: J'ANOARY 1, 1993 ' TOTAL TIME: 1 YEAR REPORT DATE: DECEMBER 31, 1993

BEFORE THERAPY AFTER THERAPY CONDITION Pt. No. CD4+ CD4+ WBC ESR These were 1 BEF AFT Sex T Lymp. N = year into Age 0-20mm treatment

210 L L L H WNL WNL WNL H +/0 +/0 M 21

211 VL VL VL VH L L L H +/H +/+ M 52

212 L L WNL H WNL WNL WNL H +/0 +/0 F 50

213 VL VL L VH +/H DC'd F 3 mos 19

214 L L L B WNL WNL WNL H +/+ +/0 F 31

215 L L L H WNL WNL WNL R +/+ +/0 M 30

216 L L L R WNL WNL WNL B +/+ +/0 M 33

217 VL L L VH L L L R +/H +/+ F 27

218 VL VL VL VH L L L H +I +/+ F AIDS 23

004808

Pt. No. Sex Age

219 M 21

220 F 19

221 M 59

222 F 36

223 M 29

224 M 26

225 F

LEGEND

- 6 -

BEFORE THERAPY CD4+ CD4+ WBC ESR

VL

VL

L

VL

VL

VL

VL

T Lymp. N = 0-20mm

L VL VH

VL VL VB

WNL WNL H

VL L VB

VL VL VB

VL VL VH

VL VL VB

AFTER THERAPY These were 1 year into treatment

WNL----------->H

WNL------------>

L L L H

L WNL WNL H

CONDITION BEF AFT

+/H +/0

+/ DC'd AIDS 1 mo

+/+ +/0

+/H +/0

+/ DC'd AIDS 9 wks

+/ +/+ AIDS

+/ DC'd AIDS 5 mos

Results will be reported as follows in accordance with standard laboratory values. This report is for qualitative discussion versus quantitative.

H • WNL • L • NC •· VL • VH •

higher than normal. within normal limits. lower than normal. no change. very low (severe). very high (severe).

004808

- 7 -

CONDITION SCALE

+/f/J +/+ +/H +/AIDS DC'd

DISCUSSION

----I: indicates HIV positive with symptoms. indicates HIV positive with slight symptoms. indicates HIV positive with moderate symptoms. indicates HIV positive with AIDS. Deceased/date post therapy in days - weeks - months.

As one can see with use of Immu.Stim-vc and the entire protocol most patients at varying levels of HIV/AIDS showed a qualitative improvement in the general health condition. When comparing ten patients HIV positive with moderate symptoms (+/H), the results were as follows:

% Improvement•

100%

75%

50%

25%

DC'd -

1 2 3 4 5 6

control group/no treatment.

7 8 9 10

0 X -= treatment group/treatment with ImmuStim-vc and protocol.

Therefore, review of ten randomly selected patients shows an overall improvement of 36% in the named parameters. Further, when reviewing quality of life and longevity of the fifteen patients studied, 75% showed improvement in the parameters and quality of life.

• See the LEGEND and CONDITION SCALE.

~ 004808

- 8 -

CONCLUSION

Therefore, as one can see from this study, ImmuStim-vc and the Caplinger et al. protocol showed a marked improvement, in both the laboratory parameters and quality of life of those patients reported. Once again, while ImmuStim-vc and the protocol is not a cure for HIV/AIDS, it does show great promise for quality of life changes, life extension, and maintenance of life.

BIBLIOGRAPHY/REFERENCES

1. Caplinger, G. E. , "Immune-Therapy As Primary Therapy," BWI Press, May 1990.

2. Caplinger, G. E., "The Utilization of Amino Acids in the Treatment of Chronic Degenerative Disease," 1988.

3. Caplinger, G. E., "Effects of Biological, Biological Response Modifiers and Nutritional Supplementation in Patients with Various Types of Cancer in Attempt to Reactivate Complete Immune Response," 1990.

4. Caplinger, G. E., 0 HIV/AIDS: A Proposal for Successful Therapy and Subsequent Remission," 1990.

5. Kimball, J. W. Introductjon to Immunology, 3rd ed. New York: Macmillan Publishing, Co., 1990.

6. Lindner, J., and Purtilo, D. T. "Current Concepts of Immunodeficiency Disorders," Modern Pathology 3(4) :524-44, 1990.

7. Broder, s. "Targeted Therapy Against Human Immunodeficiency Virus," Crjtjcal Care Medjcjne 18(2):S118-125, February 1990.

8. Gottlieb, M. s. "2',3'-Dideoxyinosine in Patients with AIDS or ARC," AIDS Clinjcal Digest 2(23):89-90, 1990.

9. Graziano, F. M., and Lemanske, R. F. Cl1n1cal Illllllunology.

10.

Baltimore: Williams & Wilkins Co., 1989.

McMahon, K., and Coyne, N. with AIDS, 11 Seminars in November 1989.

"Symptom Management in Patients Oncology Nursing 5(4):289-301,

004808

- 9 -

11. Roitt, I. Essential I111111unology. Boston: Blackwell Scientific Publications, 1988.

12. Webster, A.D., ed. I111111unodefic1ency and Disease. Hingham, Mass.: Kluwer Academic Publishers, 1988.

THIS IS A REPRINT OF AN ARTICLE TO APPEAR IN THE BWI JOURNAL OF MEDICINE. PRE-RELEASE NOT TO BE COPIED OR RELEASED TO ANY OTHER PERSON.

For ReprJnts:

BWI Hospitals and Clinics c/o Calle Cervantes #57 Z-1 Santo Domingo Dominican Republic

004808

-

AN INNOVATIVE APPROACH TO CANCER THERAPY -AN IMMUNOLOGICAL APPROACH

Caplinger, Gregory E.

ABSTRACT

Over the many years of cancer research and therapy there is still much debate as to the cause or causal factors. Much research and subsequent therapy has been directed towards a specific cause of a specific cancer.

Caplinger et al. 1•2•3 believes that a common biochemical phenomena exists with all malignancies which has been previously shown by the Nobel laureate, Dr. Otto Warburg, and subsequently by NCI research scientist, Dr. Dean Burke. When the cellular function, and more specifically the mitochondria, of the cell is examined, it is found to be anaerobic in the "cancer state" versus aerobic in the "healthy state."

Further, there exists Free Radical Pathogens (FR,P's) which are a result of split electrons in the cancer patient.

Therefnre, the discnvery of a general immunological protocol with specific aetion has been utilized in over a thousand eanr:er patients (mixed). The use of ImmuStim-CA/CAP Immunologir:al Protocolft has demonstrated a signifieant efficacy in most conr:erns. The results are discussed and summarized below.

INTRODUCTION

As previously noted, much attention to date has been the search for the specific cause(s) of specific cancers. Neoplastic cells differ from normal cells in size and function. Further, as proposed by Warburg, they are anaerobic and as q~oposed by others, they contain FRP's and thus unpaired electrons.·

Over the many years ef cancer research the Americans, and subsequently the international community, have found efficacious four forms of therapy: ( 1 ) ~urgery, ( 2) Chemotherapy, ( 3) Radiation, and (4) Immunotherapy.

Currently, many clinicians and scientists feel that Immunotherapy not only is effective but in comparison very non-toxic.

The approach of Caplinger 1•'• 3 et al. is that of nonspecific immunostimulation with specific anticarcinogenic activity. The use of ImmuStim-CA/CAP Immunological Protocolft uses biological agents to stimulate the body's reticuloendothelial system, augmenting the patient's own immunosurveillance and combating the immunosuppressive effects of cancer and its treatment.

----•-•--·-~ ------~--· . ·-- - --- -- . ----·· - -

'"''i11tlt : ,i.,:_i.,! -• , ,. \ "I. ,,o:-,,,,.;.; '4' •

- 2 -

As a major biological component of the vaccine, Interleukin-2 (IL2) not only serves as a general immune stimulant, hut activates TIL's (Tumor Infiltrating Lymphocytes) which act as macrophages to attack and eliminate neoplastic cells. 8 To summarize the effects of ImmuSt im-CA/CAP Immunological Protocol"'", one observes the following:

I. Stimulate T cells and macrophages to destroy neoplastic cells.

II. Stimulate cell mediated humoral and general immunity/immune response.

III. Oxidize any existing Free Radical Pathogens (FRP's).

IV. Stimulate and activate NK (Natural Killer) cells to destroy neoplastic cells.

V. Give the needed nutritional support.

VI. Improve the general quality of life.

PROTOCOL

I. Immustim-CA Vaccine

o Given in doses of 0.10-0.25 cc SC 1-3 times weekly and then decreasing as indicated.

II. Parenteral Therapy: (IV)

o Amino acids 3. 5-5. 0% (Aminosyn from Abbott) given in doses of 100 ml - 250 ml daily and then as indicated.

o Nutritional therapy which consists of:

DATA SUMMARY

D5W ) B Vitamins ) Vitamin C ) Minerals )

100 ml given concurrently with the amino acids.

In the staging and grading of malignant disease normally the international staging system of TMN is utilized (tumor size, metastatic progress, nodal involvement). For more simplistic: comparisons the use of an older system, somewhat traditional has been utilized even though all data for official records has been reported using TMN.5 . --

t. · 0 0 4 8 O 8

1 ·

PATIENT NUMBERS (Nu111ber in the

Treatment Group)

15

6

5

7

3

2

9

11

5

9

5

3

.,

- 3 -

SUMMARY OF DATA*

TYPE OF MALIGNANCY

STAGE (Before

initiating treatment­

traditionally Staging I-IV)

Adenocarcinoma It, III of breast

Infiltrating Ill Ductal Cell Carcinoma

Acute Lymphocytic Leukemia

III

TREATMENT** AVG. TIME OF

TREATMENT

STAGE (Post-Treatment) Jan. 1, 1994

1. 2

1, 2 • 7

1. 2

Stage

Time Since Therapy & Status -Jrlrlc

6 mos. Remission 11 7 Yrs/L-MT 2 I, 1 II, 1 DC

8-9 mos. Remission 4 4 Yrs/L-DC-MT 1 DC, 1 I

4-11 mos. Remission 4 1 I

3.5 Yrs/L-MT

Oat Cell I. II, III, IV 1, 2, 3, 7 3-9 mos. Remission 3 2 I, 2 DC

6 Yrs/L-DC-MT Carcinoma-Lung

Hodgkin's II. III Lynaphoma

Multiple III Myela&

Non-Nodgkin's t, II. III Lyaqmoaa

1. 2 5-13 mos. Remission 3

1. 2, 7 4-11 111Os. Remission 2

1, 2, 3. 7 5-15 mos. Remission 5 2 I, 2 DC

6 Yrs/L-MT

4 Yrs/L-MT

5 Yrs/L-DC-MT

Adenucarcin0111a I, II. III. IV 1, 2. 7 of eolon

7-16 mos. Remission 5 5 Yrs/L-DC-MT 2tI,2I,2DC

Adenocarcinoma III, IV of icolon with bome •ts

Adehc,carcinoma I, II. III of ;pn,state

Adenucarcin0111a III. IV of prostate with ane 11ets

Aden0011"Cin0111a I, II of rovary

Dmwsia I, II, III cosr.iv:tmil cancer-

1, 2, 3, 7 9-17 mos. Remission 2 3 DC

1, 2, 3, 7 4-11 mos. Remission 6 1 I, 1 II, 1 DC

1. 2, 3, 7 5-15 mos. Remission 2 1 III, 1 DC

1, 2, 7

1, 2, "I

4-11 mos. Remission 2 1 II

3-9 1110s. Remission 5 1 I, 1 DC

5 Yrs/L-DC-MT

3 Yrs/L-DC-MT

4 Yrs/L-DC-MT

3 Yrs/L-MT

5 Yrs/L-DC-MT

004808

PATIENT NUMBERS (Number in the

Treatment Group)

3

, 3

2

5

4

3

,.

3

7

1

3

4

TYPE OF MALIGNANCY

Glioblastoma Multiforme

Astrocytoma

Thyroid Carcinoma

Squamous Cell Carcinoma (Lung)

Adenocarcinoma (Lung)

Gastric Carcinoma (Stomach)

Adenocarcinoma of Pancreas (Head)

Renal cell r.arcinnma

Hepatnma (I iver)

Fndnmetrial Carcinnma

~uamnu!; cell Carcinnma nf Vagina

Adenncarcinnma nf Rre;:a!;t with aaP.t!; tn nv;:ary

O,;tAn,;arcnm;:a

STAGE (Before

initiating treatment­

traditionally Staging I-IV)

III

III

II, III

III

II, III

II, III, IV

TTT, TV

T, TT

TT, TTT

T, TT, TTT, TV

TTT

TT, TV

TTT

- 4 -

TREATMENT* AVG. TIME OF

TREATMENT

1 r 7 ,, mos.

1 r 3, 7 9 mos.

1 r 3, 7 6 mos.

1 r 2 9 mos.

1 r 2, 7 5-14 mos.

1 r 2, 7 7-18 mos.

1 r ?. , 7 13-?1 RIO!;.

1, ,, 3, 7 9-14 !Rn!;.

1, 7 7-11 mn!;.

1, , , 3, 7 5-15 Rln!;.

1, ,, 3, 7 9 mn!;.

1, ,, 3, 7 6-14 !Rn!;.

1 , ,, 3 ,7 5-1R mn,;.

STAGE (Post-Treatment) Jan. 1, 1994

Stage

Remission , 2 DC

, DC

Remission 3

2 DC

Remission 3 2 I

Remission 2 , IV, 1 DC

RemissiQn 'l , nc

Remi!;!;inn , 1 nr.

Remi!;!;inn , 1 nc

Remi!;!;inn 4 1 T, 1 TTT, 1 nc

1 nc

Remi!;!;inn 1 1 TT, 1 nc

Remi:i;:i;inn 3 1 nc

Time Since Therapy & Status~

4 Yrs/L-DC-MT

5 Yrs/L-MT

4 Yrs/L-MT

5 Yrs/L-DC-MT

4 Yr!;/1-0C-MT

5 Yr!;/1-nr.-MT

fi Yr!;/1-nr.-MT

7 Yr!;/1-0C-MT

fi Yr!;/1-0C-MT

4 Yr,;/1-nr.-MT

004808

' '

'·.,'"" , ··.: . , ; . - [

'

- fi -

Initial levAl nf malignanr:y without metai;;tatir. disease, withnut nodes.

Stage II OP.VP.}OpP.d nP.nplasm witho11t nndP.R, witho11t mP.taRtatir: dP.VP.lnpmP.nt.

StagP. ITT - OP.vP.1 opP.d di RP.ARP., pnR it i VP. nndP.s ( mu 1 t 1 p 1 P.) a.nrl with pnRRihlP. mP.taRtat1r. dP.VP.lopmP.nt.

Stage. TV TArminal N-StagP. of dAvA 1 opmAnt.

A 11 n11mhA1°R i • P.. StagA and TrP.atmP.nt ti mP.R arP. rP.portP.d aR an avAragA duA to thP. fact that mor;t r.atP.goriAR r:onsiRt nf morP. than one. patiAnt.

**TT'AatmAnt(s)

#1 ImmuStim-CA/CAP Tmmunolngical PT'otocol.

#2 #1 plus general r.hemothP.rapy prntocol as T'e.commP.nde.d by ASCO hut fT'actionate.d.

#3 #1, #2, and T'adiation theT'apy.

#4 #1, #3.

#5 ChemotheT'apy.

#6 Radiation the.,.apy.

#7 SurgAT'Y - Aurgi ca 1 p1°nt:AdurA.

••• Pat1Anti; pnAt thAT'apy arA rAporte.d as numhP.r of years af.tP.r t1°AatmAnt', nc' d (DAcAaRAd), r. (T,iving), MT (Ma intf:manr.A ThP.-rapy).

004808

- 6 -

DISCUSSION

Thus, upon evaluation of ImmuStim-CA/CAP Immunological Protocol one can observe a significant benefit from the therapy, and one can also see the advantages of concurrent use of other therapies.

In the evaluation of patients one can observe:

Patients Treated Patients In Remission Patients Living and in Remission Patients Deceased

I

128 76

101 27

Therefore, 78% of all treated patients showed a significant improvement in condition, quality of life, and disease state. Also, noted is 59% achievement of ~emission which for the purpose of the study is defined as a disease free state. Of those studied, 21% died at various stages of the neoplastic process.

To date over 1 , 200 patients with various neoplasms have been treated and many are under current therapy. As was previously stated, ImmuStim-CA/CAP Immunological Protocol is not a cure for neoplastic disease, hut an effective adjunctive therapy.

CONCLUSION

In view of the data reported to date (January 1, 1994), one can clearly observe the following:

I. Function

A. Efficacious s.• Strong Immunoaugmentative Biological Pharmaceutical c. Non-Toxic

II. Usage

A. Easy patient compliance B. Cost-effective C. Ambulatory use is possible

III. Effectiveness

A. Produces/facilitates remission B. Increases longevity c. Improves quality of life D. No risk to patient E. Can he and is recommended to he used concurrently with

other therapies

004808

- 7 -

To date most patients have continued on a maintenance program. Even though the vaccine and protocol have been studied and used clinically for up to ten (10) years, there are still questions to be answered.

BIBLIOGRAPHY/REFERENCES

1 . Caplinger, G. E. , 11 Immuno-Therapy As Primary Therapy, 11 BWI Press, May 1990.

2. Caplinger, G. E., "The Utilization of Amino Acins in the Treatment of Chronic Degenerative Disease," 1988.

~- Caplinger, G. E., "Effects of Biological, Biological Response Modifiers and Nutritional Supplementation in Patients with Various Types of Cancer in Attempt t'-' Reactivate Complete Immune Response," 1990.

4. A-rlin, z., et al. "A New Regimen of Am,;acrine with High Dose Cytarahine is Safe and Effective Therapy for Acute LeukAmia, 11

Journal of Cl fnical Oncology 5(::n :.171-75, March 1987.

5. Beahrs, o. H., et al. Manual for Staging of Cancer, 3rd ed. Philadelphia: 3. B. Lippincott Co., 1988.

6. Casciato, D. A., and Lowitz, B. Manual of Clinical Onr:ology, 2nd ed. Boston: Little, Brown & Co., 1988.

7. Devita, v., et Oncology, 3rd ed.

al. Canr:er Principles and Prar::tice of Philadelphia: 3. B. Lippincott Co., 1989.

8. Mccance, K., and Huethe-rs, s. Pathophysiology and the Biologic Basis for Disease 1n Adults and Children. St. Louis: Mosby-Year Book, Inc., 1990.

9. Oncology Nursing Society Clinical Practice Committee. "Cancet' Chemotherapy Guidelines," Oncology NurR1ng Society, 1988.

~- 0048 08